Xiao Jiao1, Jianyin Zou1, Pin Zhang2, Haoyong Yu3, Jianzhong Di2, Xiaodong Han2, Shankai Yin1, Hongliang Yi4. 1. Department of Otolaryngology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Otolaryngology Institute of Shanghai Jiao Tong University, 600 Yishan Road, Shanghai, 200233, China. 2. Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China. 3. Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, 600 Yishan Road, Shanghai, 200233, China. 4. Department of Otolaryngology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Otolaryngology Institute of Shanghai Jiao Tong University, 600 Yishan Road, Shanghai, 200233, China. yihongl@126.com.
Abstract
BACKGROUND: Bariatric surgery can effectively treat obesity and improve OSAHS. However, the exact underlying mechanisms remain unclear. The objective of this follow-up study is to explore the main factors associated with the efficacy of Roux-en-Y gastric bypass surgery (RYGB) on obstructive sleep apnea-hypopnea syndrome (OSAHS). METHODS: A total of 39 OSAHS patients with obesity and type 2 diabetes mellitus (T2DM) who had received RYGB surgery were recruited. A polysomnography test was carried out in all subjects before surgery and postoperative 6 to 12 months, and the following tests were performed: fasting glucose, lipid profile, electrolyte levels, and liver and kidney function tests. The paired Student's t test, Pearson test, Spearman correlation test, and multiple linear regression analysis were used to explore the effects of RYGB surgery on these indices and investigate the main factors associated with postoperative efficacy. RESULTS: RYGB surgery significantly lowered the apnea-hypopnea index (AHI), body mass index (BMI), and concentrations of total albumin, prealbumin, retinol-binding protein, total cholesterol, triglycerides, fasting blood glucose, albumin, and C-reactive protein, while postoperative blood magnesium levels were significantly increased (p < 0.05). Changes in the AHI (delta AHI) were correlated with delta BMI (r = 0.408, p = 0.010) and delta prealbumin levels (r = 0.495, p = 0.001). However, no significant correlation was found between delta BMI and delta prealbumin. The delta AHI were assessed by multiple linear analysis as follows: delta AHI = 0.105 × (delta prealbumin) + 1.509 × (delta BMI) + 1.006. CONCLUSIONS: RYGB is an effective therapeutic option for OSAHS patients with obesity and T2DM; the potential factors associated with postoperative efficacy include changes in BMI and prealbumin levels.
BACKGROUND: Bariatric surgery can effectively treat obesity and improve OSAHS. However, the exact underlying mechanisms remain unclear. The objective of this follow-up study is to explore the main factors associated with the efficacy of Roux-en-Y gastric bypass surgery (RYGB) on obstructive sleep apnea-hypopnea syndrome (OSAHS). METHODS: A total of 39 OSAHSpatients with obesity and type 2 diabetes mellitus (T2DM) who had received RYGB surgery were recruited. A polysomnography test was carried out in all subjects before surgery and postoperative 6 to 12 months, and the following tests were performed: fasting glucose, lipid profile, electrolyte levels, and liver and kidney function tests. The paired Student's t test, Pearson test, Spearman correlation test, and multiple linear regression analysis were used to explore the effects of RYGB surgery on these indices and investigate the main factors associated with postoperative efficacy. RESULTS: RYGB surgery significantly lowered the apnea-hypopnea index (AHI), body mass index (BMI), and concentrations of total albumin, prealbumin, retinol-binding protein, total cholesterol, triglycerides, fasting blood glucose, albumin, and C-reactive protein, while postoperative blood magnesium levels were significantly increased (p < 0.05). Changes in the AHI (delta AHI) were correlated with delta BMI (r = 0.408, p = 0.010) and delta prealbumin levels (r = 0.495, p = 0.001). However, no significant correlation was found between delta BMI and delta prealbumin. The delta AHI were assessed by multiple linear analysis as follows: delta AHI = 0.105 × (delta prealbumin) + 1.509 × (delta BMI) + 1.006. CONCLUSIONS: RYGB is an effective therapeutic option for OSAHSpatients with obesity and T2DM; the potential factors associated with postoperative efficacy include changes in BMI and prealbumin levels.
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: Nora Klöting; Timothy E Graham; Janin Berndt; Susan Kralisch; Peter Kovacs; Christopher J Wason; Mathias Fasshauer; Michael R Schön; Michael Stumvoll; Matthias Blüher; Barbara B Kahn Journal: Cell Metab Date: 2007-07 Impact factor: 27.287
Authors: Tatiana F S Teixeira; Maria Carmen Collado; Célia L L F Ferreira; Josefina Bressan; Maria do Carmo G Peluzio Journal: Nutr Res Date: 2012-09-07 Impact factor: 3.315
Authors: Orfeu M Buxton; Milena Pavlova; Emily W Reid; Wei Wang; Donald C Simonson; Gail K Adler Journal: Diabetes Date: 2010-06-28 Impact factor: 9.461
Authors: David Kent; Jeffrey Stanley; R Nisha Aurora; Corinna G Levine; Daniel J Gottlieb; Matthew D Spann; Carlos A Torre; Katherine Green; Christopher G Harrod Journal: J Clin Sleep Med Date: 2021-12-01 Impact factor: 4.062